AI is a game of kings, and OpenAI knows it
DUBLIN - Investment firm Citadel Group has disclosed a 1.32% stake in Mural Oncology plc, according to a regulatory filing published Thursday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 229,717 shares representing interests in the Dublin-based oncology company as of October 1, 2025. This includes 216,317 owned or controlled shares and 13,400 shares through stock-settled derivatives.
The filing also reveals Citadel maintains short positions equivalent to 1.11% of Mural Oncology’s shares, primarily through stock-settled derivatives totaling 193,400 shares.
The disclosure details several transactions conducted by Citadel, including purchases of 1,143 shares at prices ranging from $2.07 to $2.08 per share, and sales of 43,076 shares at similar price points.
Additionally, Citadel reported options positions including purchased call options with various strike prices from $2.50 to $7.50 and expiration dates extending to March 2026, as well as put options with a $2.50 strike price expiring between December 2025 and January 2027.
Irish regulations require investors to disclose positions representing 1% or more of a company’s shares during takeover situations, though the filing does not specify any current takeover activity involving Mural Oncology.
The information was provided through a Form 8.3 filing with the Irish Takeover Panel, based on a press release statement issued via the Regulatory News Service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.